Seeking Alpha
Research analyst, IPOs, long/short equity
Profile| Send Message|
( followers)  

The following IPOs are expected to price this week:

Aratana Therapeutics (NASDAQ:PETX), which is developing medications for cats and dogs based on therapies for humans, plans to raise $51 million by offering 4.3 million shares at a price range of $11.00 to $13.00. At the midpoint of the proposed range, Aratana Therapeutics would command a market value of $217 million. Aratana Therapeutics was founded in 2010. The Kansas City, KS-based company plans to list on the NASDAQ under the symbol PETX. Stifel and Lazard Capital Markets are the joint bookrunners on the deal.

bluebird bio (NASDAQ:BLUE), which is developing gene therapies for severe genetic and orphan diseases, plans to raise $75 million by offering 5.0 million shares at a price range of $14.00 to $16.00. At the midpoint of the proposed range, bluebird bio would command a market value of $374 million. bluebird bio, which was founded in 1992, booked $1 million in sales over the last 12 months. The Cambridge, MA-based company plans to list on the NASDAQ under the symbol BLUE. J.P. Morgan and BofA Merrill Lynch are the joint bookrunners on the deal.

Gogo (NASDAQ:GOGO), the leading provider of in-flight WiFi on commercial and business jets, plans to raise $176 million by offering 11.0 million shares at a price range of $15.00 to $17.00. At the midpoint of the proposed range, Gogo would command a market value of $1.4 billion. Gogo, which was founded in 1991, booked $250 million in sales over the last 12 months. The Itasca, IL-based company plans to list on the NASDAQ under the symbol GOGO. Morgan Stanley, J.P. Morgan and UBS Investment Bank are the joint bookrunners on the deal.

PTC Therapeutics (NASDAQ:PTCT), a biotech targeting rare forms of muscular dystrophy and cystic fibrosis, plans to raise $100 million by offering 6.9 million shares at a price range of $13.00 to $16.00. At the midpoint of the proposed range, PTC Therapeutics would command a market value of $322 million. PTC Therapeutics, which was founded in 1998, booked $29 million in sales over the last 12 months. The South Plainfield, NJ-based company plans to list on the NASDAQ under the symbol PTCT. J.P. Morgan and Credit Suisse are the joint bookrunners on the deal.

Regado Biosciences (NASDAQ:RGDO), which is developing break-through anticoagulant system for cardiovascular surgeries, plans to raise $75 million by offering 5.0 million shares at a price range of $14.00 to $16.00. At the midpoint of the proposed range, Regado Biosciences would command a market value of $219 million. Regado Biosciences, which was founded in 2001, booked $0 million in sales over the last 12 months. The Basking Ridge, NJ-based company plans to list on the NASDAQ under the symbol RGDO. Cowen & Company and BMO Capital Markets are the joint bookrunners on the deal.

Votorantim Cimentos S.A. (VEBM), Brazil's largest cement producer with 37% market share, plans to raise $3.4 billion by offering 200.0 million shares at a price range of $15.59 to $18.51. At the midpoint of the proposed range, Votorantim Cimentos S.A. would command a market value of $17.9 billion. Votorantim Cimentos S.A., which was founded in 1933, booked $4.9 billion in sales over the last 12 months. The São Paulo, Brazil-based company plans to list on the NYSE under the symbol VEBM. Morgan Stanley, J.P. Morgan, Itau BBA and Credit Suisse are the joint bookrunners on the deal. (Please note: Dual listing on NYSE and São Paulo Stock Exchange.)

Last week, there were 2 IPO pricings. Gigamon (NYSE:GIMO), which provides data traffic management software-based appliances, was the week's winner, ending up 50% from its IPO price.

Source: 6 U.S. IPOs Planned For The Week Of June 17